United States - English - NLM (National Library of Medicine)

clinical solutions wholesale - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir 400 mg - acyclovir is indicated for the acute treatment of herpes zoster (shingles). acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. acyclovir is indicated for the treatment of chickenpox (varicella). acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir 800 mg - herpes zoster infections: acyclovir tablets are indicated for the acute treatment of herpes zoster (shingles). genital herpes: acyclovir tablets are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. chickenpox: acyclovir tablets are indicated for the treatment of chickenpox (varicella). acyclovir tablets are contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

United States - English - NLM (National Library of Medicine)

nucarepharmaceuticals, inc. - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir 400 mg - herpes zoster infections: acyclovir tablets, usp are indicated for the acute treatment of herpes zoster (shingles). genital herpes: acyclovir tablets, usp are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. chickenpox: acyclovir tablets, usp are indicated for the treatment of chickenpox (varicella). acyclovir tablets are contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir 400 mg - herpes zoster infections: acyclovir tablets, usp are indicated for the acute treatment of herpes zoster (shingles). genital herpes: acyclovir tablets, usp are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. chickenpox: acyclovir tablets, usp are indicated for the treatment of chickenpox (varicella). acyclovir tablets are contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

United States - English - NLM (National Library of Medicine)

renaissance pharma, inc. - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir 200 mg in 5 ml - herpes zoster infections: acyclovir is indicated for the acute treatment of herpes zoster (shingles). genital herpes: acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. chickenpox: acyclovir is indicated for the treatment of chickenpox (varicella).  acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

United States - English - NLM (National Library of Medicine)

avpak - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir 200 mg - herpes zoster infections: acyclovir is indicated for the acute treatment of herpes zoster (shingles). genital herpes: acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. chickenpox: acyclovir is indicated for the treatment of chickenpox (varicella). acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

United States - English - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 5 mg - cyclobenzaprine hcl tablets usp are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. cyclobenzaprine hcl should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.   cyclobenzaprine hcl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamine oxidase (mao) inhibitors or within 14 days after their discontinuation. h

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 5 mg - cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamine oxidase (mao) inhibitors or with

United States - English - NLM (National Library of Medicine)

citron pharma llc - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 5 mg - cyclobenzaprine hydrochloride tablets, usp are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. cyclobenzaprine hydrochloride tablets, usp should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. cyclobenzaprine hydrochloride tablets, usp have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamin

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg - cyclosporine capsules usp modified are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. cyclosporine capsules usp modified have been used in combination with azathioprine and corticosteroids. cyclosporine capsules usp modified are indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. cyclosporine capsules usp modified can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. cyclosporine capsules usp modified are indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., puva, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated. while rebound rarely occurs, most patients will experience relapse with cyclosporine capsules usp modified as with other therapies upon cessation of treatment. cyclosporine capsules usp modified are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules usp modified. psoriasis patients who are treated with cyclosporine capsules usp modified should not receive concomitant puva or uvb therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules usp modified.